Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

These aren't for the faint of heart.

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

AI systems are already writing the code used to build better AI. Researchers are now asking whether that feedback loop could ...

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

Cathie Wood's ARK Invest purchased $41.2M in Tesla (TSLA) and $2.3M in Bullish while selling $25.3M in Roku shares. See full trade breakdown here.

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most ...

: Ark simultaneously rebalanced its portfolio, adding names such as Palantir, SpaceX, and Cerebras while exiting positions ...

Anthropic said on Thursday frontier AI developers should establish a coordinated, verifiable way to slow down or temporarily pause development if advanced systems begin improving themselves faster ...